Find your next paid study

Blueprint Medicines CorporationNCT07629960

Phase 2

Study of Trilaciclib and Lurbinectedin in Small Cell Lung Cancer

Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell …

Lung CancerSmall-cell Lung Cancer

UNC Lineberger Comprehensive Cancer CenterNCT05578326

~$10 – $6,250

Randomised Clinical TrialDouble BlindDengue+2 more

A Phase I Study of the Safety, Immunogenicity and Efficacy of a Tetravalent Dengue VLP Vaccine (VLPDEN-02) Against DENV-3 Challenge in Healthy Adults

This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study. Forty-two flavivirus-naïve adults will be enrolled and will receive 3 a…

VLP TherapeuticsNCT07831473

Non Small Cell Lung CancerEsophageal CancerSmall Cell Lung Cancer+7 more

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung C…

SystImmune Inc.NCT05983432

Phase 3

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) tr…

Non-small Cell Lung Cancer

~$10 – $7,500

AstraZenecaNCT06692738

Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer (TNBC)HR+ Breast Cancer+8 more

A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SHY-ONC6 in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity o…

SHY TherapeuticsNCT07705334

Phase 2

A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of Navlimetostat (BMS-986504) Monotherapy and in Combination With Izalontamab Brengitecan in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss After Progression on Prior Therapies

The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in pa…

Carcinoma, Non-Small-Cell Lung

Bristol-Myers SquibbNCT06855771

~$10 – $7,500

Locally Advanced or Metastatic Solid Tumors

A Phase 1b/2 Study of ASP388B as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors

This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given …

Astellas Pharma Global Development, Inc.NCT07730021

Medtronic Product Surveillance Registry

The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The R…

Cardiac Rhythm DisordersUrological DisordersNeurological Disorders+13 more

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Non-Small Cell Lung Cancer

Summit TherapeuticsNCT06767514

Phase 2

A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer

This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tiss…

Locally Advanced Adrenal Cortical CarcinomaMetastatic Adrenal Cortical CarcinomaRecurrent Adrenal Cortical Carcinoma+3 more

National Cancer Institute (NCI)NCT06900595

~$10 – $5,625

Advanced Solid TumorMetastatic CancerCutaneous Melanoma+1 more

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imnesk…